A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.

[1]  C. Rudin,et al.  Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study , 2019, Clinical Cancer Research.

[2]  L. Horn,et al.  Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer. Reply. , 2019, New England Journal of Medicine.

[3]  Omer Diker,et al.  Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer. , 2019, The New England journal of medicine.

[4]  W. Miller,et al.  Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. , 2018 .

[5]  C. Rudin,et al.  Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study , 2018, Pneumologie.

[6]  R. Salgia,et al.  Managing Patients With Relapsed Small-Cell Lung Cancer. , 2018, Journal of oncology practice.

[7]  D. Jäger,et al.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. , 2016, The Lancet. Oncology.

[8]  C. Rudin,et al.  Small cell lung cancer: Where do we go from here? , 2015, Cancer.

[9]  J. von Pawel,et al.  Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Edward L Spitznagel,et al.  Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Jeffrey W. Clark,et al.  A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  J. Carmichael,et al.  Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Weiss,et al.  A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  B. Teicher,et al.  Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo , 1998, Cancer Chemotherapy and Pharmacology.

[15]  A. Tolcher,et al.  A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  C. Whitacre,et al.  Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process. , 1997, Cancer research.

[17]  R. Kim,et al.  Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice , 1992, International journal of cancer.

[18]  T. Tsuruo,et al.  Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. , 1990, Cancer research.

[19]  T. Andoh,et al.  Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines. , 1990, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[20]  D. Booser,et al.  Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non‐small cell lung cancer , 1989, Cancer.

[21]  J. Wang.  DNA topoisomerases. , 1985, Annual review of biochemistry.

[22]  L. Liu,et al.  Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.

[23]  S. Wallace,et al.  Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Liu,et al.  Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.

[25]  K W Kohn,et al.  Protein-associated DNA breaks in cells treated with adriamycin or ellipticine. , 1978, Biochimica et biophysica acta.